Insider Transactions in Q2 2024 at Rhythm Pharmaceuticals, Inc. (RYTM)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2024
|
David W J Mcgirr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
-
|
|
Jun 21
2024
|
Stuart A Arbuckle Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
-
|
|
Jun 21
2024
|
Christophe Jean Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
-
|
|
Jun 21
2024
|
Camille L Bedrosian Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
-
|
|
Jun 21
2024
|
Edward T Mathers |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
-
|
|
Jun 21
2024
|
Lynn A. Tetrault Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
-
|
|
Jun 21
2024
|
Jennifer L Good Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
-
|
|
May 09
2024
|
Joseph Shulman Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
3,984
-90.57%
|
$151,392
$38.74 P/Share
|
|
May 09
2024
|
Joseph Shulman Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,984
+49.81%
|
$23,904
$6.8 P/Share
|
|
Apr 14
2024
|
Yann Mazabraud EVP, Head of International |
SELL
Exercise of conversion of derivative security
|
Direct |
10,375
-22.93%
|
-
|
|
Apr 02
2024
|
Christopher Paul German Corporate Controller & CAO |
SELL
Open market or private sale
|
Direct |
368
-31.64%
|
$15,088
$41.76 P/Share
|